Clarient, Inc. (CLRT)

All Comments on CLRT

  • commenter
    User 155044
    Sep 30 10:33 AM
    Cancer Stocks Plunge Following ASCO Meeting [view article]
    EXCELLENT JOB, Reply
  • commenter
    Olboy2
    Aug 13 02:56 PM
    Cancer Stocks on the Go: Winners and Losers [view article]
    I agree with paviov, However I would like to know about the new developments the phase II and III studies that are going well, where is the advancement taking place, how close to a cure, what company has the potential winning drug ?? Reply
  • commenter
    ggrail
    Jun 13 10:46 AM
    Clarient, Inc.: Clarifying the Complexities of Cancer [view article]
    A screaming buy under 2 Reply
  • commenter
    ggrail
    May 03 12:46 PM
    General Discussion on CLRT
    I think Clarient is a buy. They stumbled when they discovered a weakness last quarter and moved rapidly to cure the cause and mute the effect. They have followed up with an exceptional quarter.

    Stock ran back up Thur-Fri to the levels before their flub. It should have gone 25% higher, imo. Strong sales, exceptional execution in the lab, and now gaining economies of scale in their model coupled with new operational and financial metrics and a Medicare price increase blip should surprise on the up side in Q2 again.

    All this even before their new molecular diagnostics assays Insight Dx for Breast Cancer and Prostate and their HemeScan lymphoma Dx materially add to revenues.

    It's their time,


    On Apr 06 05:20 AM SeekingAlpha Editors wrote:

    > Is this a buy or a sell?     Reply
  • commenter
    SeekingAlpha
    Editors
    Apr 06 05:20 AM
    My Website
    General Discussion on CLRT
    Is this a buy or a sell? Reply
  • commenter
    bsrichard
    Mar 06 04:10 PM
    Clarient, Inc.: Clarifying the Complexities of Cancer [view article]
    Is Clarient (CLRT) a value at 1.75? Reply
  • commenter
    bsrichard
    Mar 06 03:32 PM
    Cancer Stocks Hammered Once Again [view article]
    Alan,

    What are your thoughts on Chemokine Therapeutics Corp (CHKT)?

    And Meridian Co LTD (MRDAF)?
    Reply
  • commenter
    bsrichard
    Mar 06 11:48 AM
    Cancer Stocks Hammered Once Again [view article]
    please ignore the comment above. it was posted in the wrong thread.
    Reply
  • commenter
    bsrichard
    Mar 06 11:47 AM
    Cancer Stocks Hammered Once Again [view article]
    Maybe BofA should by this one too.

    Which bank took the highly rated debt at a discount from TMA?     Reply
  • commenter
    Alan
    Brochstein
    Mar 05 07:06 PM
    My Website
    Cancer Stocks Hammered Once Again [view article]
    I don't know the company, but it sure looks interesting. Technically, it would be nice to hold 1.75. The company is seemingly deficient in cash - it would appear that there will be either an equity or debt offering this year. If they become profitable as forecast this year, the stock could get some attention - diagnostics have been hot. Reply
  • commenter
    bsrichard
    Mar 05 12:23 PM
    Cancer Stocks Hammered Once Again [view article]
    Hi Alan,
    What is your current opinion on Clarient (CLRT)?
    Thanks very much,
    Don     Reply
  • commenter
    Alan
    Brochstein
    Jun 26 03:03 PM
    My Website
    Cancer Stocks Hammered Once Again [view article]
    Thanks for the comment and the compliment. Thanks also for the information. Contact me by phone or email if you would like to discuss your ideas. Reply
  • commenter
    hpski
    Jun 26 12:45 PM
    Cancer Stocks Hammered Once Again [view article]
    Great post! It would be quite useful if your excel file could be downloaded, then someone could sort on other attributes, or even add some, e.g. #drugs in phase 3, total #drugs in pipeline, #big pharma collaborations, PADUFA dates, if any, etc. I'm offering a few comments vis-à-vis individual companies: I think EXEL, which probably has the deepest pipeline on your list, is gaining because investors believe Glaxo will take XL647. I believe it's, "show's over", for TELK (Telcyta is finito). Onyx is declining because it faces stiff competition from Pfizer's Sutent & now Wyeth's Torisol in renal cell carcinoma. Any sales increases for Onyx's Nexavar will come from off-label use in liver cancer, but that is not, in my opinion, a reason to invest. CEGE's recent decline is a gift - when European Revlimid sales appear on their balance sheet, along with clinical milestone press releases, it'll get back into the 60's. GNTA has been on a slippery slope for some time now - their CEO, Ray Warrell, is very smart, very committed, and held in high regard by his oncology peers at his alma mater, MSKCC. He is making use of FDA's dispute process for Genasense in CLL, so some investors are betting FDA will offer up a conditional approval in subsets of patients. The key here is that CLL is a very heterogeneous disease - therapy needs to be more individualized. Finally, in my opinion, ISRG is absolutely the future of surgery. Any decline into the low 130's is a bargain. Thanks again for your article! Reply
  • commenter
    Alan
    Brochstein
    Jun 18 12:54 PM
    My Website
    Cancer Stocks Slide Again [view article]
    I wanted to point out an error in the article - GNVC is developing a pancreatic cancer treatment (not vaccine). Reply
  • commenter
    Alan
    Brochstein
    Jun 11 02:51 PM
    My Website
    Cancer Stocks Plunge Following ASCO Meeting [view article]
    Miles, I have a negative bias towards small biotech companies, especially ones like this that have a terrible history of underperforming the stock market, generating losses and diluting with equity issuance. That isn't to say that one might find a diamond in the garbage can, but, I think that one is actually more likely to find a diamond in the garbage can. If one of these companies is creating a truly novel, revolutionary treatment, I personally believe that an investor would have plenty of time to buy later at a higher price and still make a ton of money.

    Note, I don't have an opinion specifically on Insmed other than my general observations in the above paragraph.     Reply
Loading...
Symbols:
Authors:
Quick Links: